Ep 18: SD101 + Pembro

Summary Sapna reveals her most used emoji is a heart (awww..... <3) and James just avoids the question. Neither has decided on their theme song as a wrestler which means they won't be quitting their day jobs anytime soon. In this episode, James and Sapna discuss the injectable treatment SD101, its mechanism, efficacy in different patient populations, and the challenges faced in its development. They explore the significance of the study results of SD101 plus pembrolizumab, particularly in PD-1 naive and refractory patients, and the implications for future research and treatment strategies in melanoma. Keywords SD101, pembrolizumab, melanoma, immunotherapy, PD-1, toll-like receptor, cancer treatment, clinical trials, efficacy, safety Takeaways SD101 shows a high response rate in PD-1 naive patients. The mechanism of SD101 involves toll-like receptor 9 agonism. Safety and tolerability of SD101 were confirmed in the study. Efficacy in PD-1 refractory patients is lower but shows potential. The study included correlative analyses that revealed immune responses. Manufacturing and development challenges have impacted SD101's progress. Not all toll-like receptor agonists have the same effects. The concept of 'turning cold tumors hot' is crucial in treatment. Future studies are needed to explore SD101's full potential. The development of SD101 has shifted focus to rare tumors. Sound Bites "High response rate in PD-1 naive patients." "Turning cold tumors hot is a challenge." "SD101 is safe and tolerable." Chapters 00:00 Introduction and Quick Questions 03:44 Overview of the SD101 Trial 05:39 Efficacy in PD-1 Naive and PD-1 Refractory Patients 08:04 Efficacy in the Refractory Setting 11:17 Development and Future of SD101 13:59 Comparison with Other Toll-Like Receptor 9 Agonists 15:51 Summary and Conclusion